| OPPOSITION | - ABELSON, M.B, "The Secret World of Pharmacokinetics: Knowing something about this area of research can help make you a better clinician", REVIEW OF OPHTHALMOLOGY, (20090220), XP002785821 | - |
| OPPOSITION | - Abelson M., Dewey-Mattia Daniel, Crawford Kathy, Andover, Mass, "The Secret World of Pharmacokinetics: Knowing something about this area of research can help make you a better clinician", REVIEW OF OPHTHALMOLOGY, (20090000), pages 1 - 10, XP002785821 | - |
| OPPOSITION | - A. HOMMER, "A review of preserved and preservative-free prostaglandin analogues for the treatment of open -angle glaucoma and ocular hypertension", Drugs of today, (20100000), vol. 46, no. 6, pages 409 - 416, XP055974495 | - |
| OPPOSITION | - A. HOMMER, "A review of preserved and preservative-free prostaglandin analogues for the treatment of open-angle glaucoma and ocular hypertension", Drugs of today, (20100000), vol. 46, no. 6, pages 409 - 416, XP055974495 | - |
| OPPOSITION | - Allergan pharmaceuticals (Pty) Ltd, "Ganfort® eye drops", Patient information leaflet, (20091009), pages 1 - 5, XP055974386 | - |
| OPPOSITION | - Anonymous, "(bimatoprost), European public assessment report", LUMIGAN - Scientific discussion, (20040000), pages 1 - 40, XP055976497 | - |
| OPPOSITION | - Anonymous, "EMEA public statement on antimicrobial preservatives in ophthalmic preparations for human use", European Medicines Agency, (20090000), page 1, XP055628980 | - |
| OPPOSITION | - Anonymous, "EMEA PUBLIC STATEMENT ON ANTIMICROBIAL PRESERVATIVES IN OPHTHALMIC PREP ARA TI ONS FOR HUMAN USE", European Medicines Agency, London, (20091208), page 1, XP055974389 | - |
| OPPOSITION | - Anonymous, "EMEA PUBLIC STATEMENT ON ANTIMICROBIAL PRESERVATIVES IN OPHTHALMIC PREP ARA TI ONS FOR HUMAN USE", European Medicines Agency, London, London, (20091208), page 1, European Medicines Agency , (20221025), XP055974389 | - |
| OPPOSITION | - Anonymous, "FACHINFORMATION (ZUSAMMENFASSUNG DER MERKMALE DES ARZNEIMITTELS)", Allergan, (20090301), Allergan, (20221031), XP055976530 | - |
| OPPOSITION | - Anonymous, "Ganfort® 300 Mikrogramm/ml +5 mg/ml Augentropfen - Allergan®", Fachinformation (zusammenfassung der merkmale der arzneimittels), (20090301), pages 1 - 4, XP055609233 | - |
| OPPOSITION | - Anonymous, "Ganfort eye drops - patient information leaflet", Allergan pharmaceuticals (Pty) Ltd, (20091000), pages 1 - 5, XP055974386 | - |
| OPPOSITION | - Anonymous, "Ganfort eye drops - patient information leaflet", Allergan pharmaceuticals (Pty) Ltd, (20091001), pages 1 - 5, Allergan pharmaceuticals (Pty) Ltd, (20221025), XP055974386 | - |
| OPPOSITION | - Anonymous, "Ganfort@", Ganfort@ 162 370 u3/u21, (20161200), page 1, XP055974396 | - |
| OPPOSITION | - Anonymous, "Medical Officer’s Review of NDA 21-275", Center for drug evaluation and research FDA, (20140314), pages 1 - 124, XP055974464 | - |
| OPPOSITION | - Anonymous, "Prescribing information of Ganfort", Allergan, Germany, (20090000), pages 1 - 9, XP055976501 | - |
| OPPOSITION | - Anonymous, "PRODUCT LEAFLET OF GANFORT@", Ganfort, (20160901), Ganfort, (20221031), XP055976531 | - |
| OPPOSITION | - Anonymous, "Product leaflet of GANFORT@ PF 0.3/5 eye drops", (20190201), (20221031), XP055976534 | - |
| OPPOSITION | - Anonymous, "PRODUCT LEAFLET OF TIMOPTIC®", (20090101), (20221031), XP055976533 | - |
| OPPOSITION | - Anonymous, "timolol maleate ophthalmic solution", Prescribing information of Timoptic in Ocudose, (20050000), pages 1 - 7, XP055976495 | - |
| OPPOSITION | - Bartlet Jimmy D., Siret D. Jaanus, "Benzalkonium Chloride and others surfactants", Clinical Ocular Pharmacology, Butterworth-Heinemann, (20080101), page 30, XP055976209 | - |
| OPPOSITION | - Bartlett Jimmy D., Et Al., "Ophthalmic Drug Formulations", Clinical Ocular Pharmacology, (20080101), page 30, Clinical Ocular Pharmacology, (20221101), XP055976543 | - |
| OPPOSITION | - Center for drug evaluation and research FDA, " Medical Officer’s Review of NDA 21-275", (20010314), pages 1 - 124, XP055974464 | - |
| OPPOSITION | - Cordeiro Francesca M., Et Al., "Efficacy of a preservative-free formulation of fixed-combination bimatoprost and timolol (Ganfort PF) in treatment-naive patients vs previously treated patients", Clinical Ophthalmology, (20150101), pages 1605 - 1611, Clinical Ophthalmology, (20221025), XP055974407 | - |
| OPPOSITION | - CORDEIRO, M. FRANCE SCA et al., "Efficacy of a preservative-free formulation of fixed-combination bimatoprost and timolol (Ganfort PF) in treatment-naive patients vs previously treated patients", Clinical Ophthalmology, (20150000), pages 1605 - 1611, XP055974407 | - |
| OPPOSITION | - D70: 2ND DECLARATION BY CHARLES S. DAVIS | - |
| OPPOSITION | - D71: EPO SUBMISSION FROM SEPTEMBER 2010 RELATING TO EP 1753 434 | - |
| OPPOSITION | - Daniel Limmer, "Remington: The Science and Practice of Pharmacy, 20th Edition /Passage/", Remington: The Science and Practice of Pharmacy, 20th Edition, Lippincott Williams & Wilkins , (20000101), page 2pp, 1398, XP055718835 | - |
| OPPOSITION | - D F Woodward, A H, Krauss -P, Chen J, Lai R K, Spada C S, Burk R M, Andrews S W, Shi L, Liang Y, Kedzie K M, Chen R, Gil D W, Kharlamb A, Ms, Archeampong A, Ling J, Madhu C, Ni J, Rix P, Usansky J, Usansky H, Ms, Weber A, Welty D, Yang W, D D, Tang-Liu -S, Garst M E, Brar B, Wheeler L A, Kaplan L J, "The Pharmacology of Bimatoprost (Lumigan™)", Survey of Ophthalmology, (20010501), vol. 45, no. suppl. 4, pages s337 - s345, XP055187907 | - |
| OPPOSITION | - Edman, "Influence of Factors Other Than Preservatives", Biopharmaceutics of Ocular Drug Delivery, (19970101), pages 243 - 259, XP093074199 | - |
| OPPOSITION | - EMEA, "Scientific Discussion (Ganfort)", (20060101), pages 1 - 37, XP055629311 | - |
| OPPOSITION | - European Medicines Agency, "EMEA PUBLIC STATEMENT ON ANTIMICROBIAL PRESERVATIVES IN OPHTHALMIC PREPARATIONS FOR HUMAN USE", London, (20091208), page 1, XP055974389 | - |
| OPPOSITION | - "Eye preparations", European Pharmacopoeia, 4th ed., Strasbourg, FR , (20010101), page 539, ISBN 978-92-8-714587-1, XP055629302 | - |
| OPPOSITION | - Gardner Martin J; Altman Douglas G, "Statistics in Medicine Confidence intervals rather than P values: estimation rather than hypothesis testing", British Medical Journal, (19860000), vol. 292, pages 746 - 750, XP055974410 | - |
| OPPOSITION | - Gardner Martin J, Altman Douglas G, "Statistics in Medicine Confidence intervals rather than P values: estimation rather than hypothesis testing", British Medical Journal, (19860315), vol. 292, pages 746 - 750, XP055974410 | - |
| OPPOSITION | - GROSS, R., "Glaucoma Medications and Their Effects on the Corneal Surface Glaucoma Medications and Their Effects on the Corneal Surface", Alcon Laboratories, (20070000), pages 1 - 14, XP055976474 | - |
| OPPOSITION | - Gross Ronald, Kahook Malik Y., Noecker Robert J., Lin Shan, Pflugfelder Stephen C., "Glaucoma Medications and their Effects on the Corneal Surface - A roundtable discussion", Supplement to Glaucoma Today, (20070701), pages 1 - 13, XP055976641 | - |
| OPPOSITION | - Hamacher T. et al., "Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis", Acta Ophthalmol, (20080101), vol. 86, no. S242, pages 14 - 19, XP055974472 | - |
| OPPOSITION | - Hamacher T., Et Al., "Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis", Acta Ophthalmol, (20080101), vol. 86, no. S242, pages 14 - 19, XP055974472 | - |
| OPPOSITION | - HANNU UUSITALO et al., "Pharmacokinetics, efficacy and safety profiles of preserved and preservative-free tafluprost in healthy volunteers", Acta Ophthalmol, (20080000), vol. 96, no. S242, pages 7 - 13, XP055974481 | - |
| OPPOSITION | - Hommer A., "A review of preserved and preservative-free prostaglandin analogues for the treatment of open -angle glaucoma and ocular hypertension", DRUGS OF TODAY, (20100101), vol. 46, no. 6, pages 409 - 416, XP055974495 | - |
| OPPOSITION | - Hommer A., "A review of preserved and preservative-free prostaglandin analogues for the treatment of open-angle glaucoma and ocular hypertension", DRUGS OF TODAY, (20100101), vol. 46, no. 6, pages 409 - 416, XP055974495 | - |
| OPPOSITION | - HOMMER, A., "A review of preserved and preservative-free prostaglandin analogues for the treatment of open-angle glaucoma and ocular hypertension", Drugs Today, (20100000), vol. 46, no. 6, pages 409 - 416, XP055974495 | - |
| OPPOSITION | - H. UUSITALO et al., "Pharmacokinetics, efficacy and safety profiles of preserved and preservative-free tafluprost in healthy volunteers", Acta Ophthalmol, (20080000), vol. 96, no. S242, pages 7 - 13, XP055974481 | - |
| OPPOSITION | - "Intraocular pressure ", Wikipedia, (20100707), URL: https://en.wikipedia.org/w/index.php?title=Intraocular_pressure&oldid=372253384, XP055976610 | - |
| OPPOSITION | - Kitazawa Y., Et Al., "Travoprost 0.004%/timolol 0.5%-fixed combination with and without benzalkonium chloride: a prospective, randomized, doubled-masked comparison of safety and efficacy", Eye, (20110101), vol. 25, pages 1161 - 1169, XP055974488 | - |
| OPPOSITION | - LAIBOVITZ R A, ET AL., "COMPARISON OF THE OCULAR HYPOTENSIVE LIPID AGN 192024 WITH TIMOLOL DOSING, EFFICACY, AND SAFETY EVALUATION OF A NOVEL COMPOUND FOR GLAUCOMA MANAGEMENT", Archives of Ophthalmology, American Medical Association, United States, United States , (20010701), vol. 119, no. 07, ISSN 0003-9950, pages 994 - 1000, XP001094959 | - |
| OPPOSITION | - Lee Wai-Yip T, "Ocular Penetration Enhancers ", Ophthalmic Drug Delivery Systems Second Edition, Revised and Expanded, (20030101), pages 281 - 307, XP093074266 | - |
| OPPOSITION | - LUMIGAN, "Medical officers review of NDA 21-275 (bimatoprost), FDA Drug Approval Package", Center for drug evaluation and research, application nymber: 21-275 - Medical review, (20010000), pages 1 - 124, XP055976433 | - |
| OPPOSITION | - Manni, G. ; Centofanti, M. ; Oddone, F. ; Parravano, M. ; Bucci, M.G., "Interleukin-1@b tear concentration in glaucomatous and ocular hypertensive patients treated with preservative-free nonselective beta-blockers", American Journal of Ophthalmology, Elsevier, AMSTERDAM, NL, AMSTERDAM, NL , (20050101), vol. 139, no. 1, ISSN 0002-9394, pages 72 - 77, XP027729149 | - |
| OPPOSITION | - Manni, G. ; Centofanti, M. ; Oddone, F. ; Parravano, M. ; Bucci, M.G., "Interleukin-1(gamma) tear concentration in glaucomatous and ocular hypertensive patients treated with preservative-free nonselective beta-blockers", American Journal of Ophthalmology, AMSTERDAM, NL , (20050101), vol. 139, no. 1, ISSN 0002-9394, pages 72 - 77, XP027729149 | - |
| OPPOSITION | - Manni G; Centofanti M; Oddone F; Parravano M; Bucci M G, "Interleukin-1β tear concentration in glaucomatous and ocular hypertensive patients treated with preservative-free nonselective beta-blockers", Am.J.Ophthalmol, (20050000), vol. 139, no. 1, pages 72 - 77, XP027729149 | - |
| OPPOSITION | - Manni Gianluca, Et Al., "lnterleukin-1B Tear Concentration in Glaucomatous and Ocular Hypertensive Patients Treated With Preservative-Free Nonselective Beta- Blockers", Am. J. Ophthalmol, (20050101), vol. 139, XP055976205 | - |
| OPPOSITION | - M. B. ABELSON, "The Secret World of Pharmacokinetics: Knowing something about this area of research can help make you a better clinician", Review of Ophthalmology, pages 1 - 10, XP002785821 | - |
| OPPOSITION | - Merck & Co., Inc., "PRESERVATIVE-FREE STERILE OPHTHALMIC SOLUTION in a Sterile Ophthalmic Unit Dose Dispenser TIMOPTIC® 0.25% AND 0.5% (TIMOLOL MALEATE OPHTHALMIC SOLUTION) in OCUDOSE® (DISPENSER)", Data Sheet, (20050701), pages 1 - 7, XP055462098 | - |
| OPPOSITION | - Netland Peter A, "GLAUCOMA MEDICAL THERAPY", Principles and Management, Second Edition , (20080101), XP055976601 | - |
| OPPOSITION | - PHILLIPS, P., "Glaucoma Eyedrops: A Fresh Look at Preservatives", EyeNet Selections, (20080000), pages 1 - 4, XP055974452 | - |
| OPPOSITION | - Phillips P., "Glaucoma Eyedrops: A Fresh Look at Preservatives", EyeNet Selections - A supplement to Eyenet Magazine, (20080101), pages 1 - 4, EyeNet Selections - A supplement to Eyenet Magazine, (20221025), XP055974452 | - |
| OPPOSITION | - Phillips P., "Glaucoma Eyedrops: A Fresh Look at Preservatives", EyeNet Selections - A supplement to Eyenet Magazine, (20080101), pages 7 - 8, XP055974452 | - |
| OPPOSITION | - P. PHILLIPS, "Glaucoma Eyedrops: A Fresh Look at Preservatives", EyeNet Selections - A supplement to Eyenet Magazine, (20080000), pages 1 - 4, XP055974452 | - |
| OPPOSITION | - R. A. LEWIS et al., "Travoprost 0.004% With and Without Benzalkonium Chloride: A comparison of Safety and Efficacy", J. Glaucoma, (20070000), vol. 16, no. 1, pages 98 - 103, XP055462693 | - |
| OPPOSITION | - R. A. Lewis Et Al., "Travoprost 0.004% With and Without Benzalkonium Chloride: A comparison of Safety and Efficacy", J Glaucoma, (20070101), vol. 16, no. 1, pages 98 - 103, XP055462693 | - |
| OPPOSITION | - T. HAMACHER et al., "Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis", Acta Ophthalmol, (20080000), vol. 86, no. S242, pages 14 - 19, XP055974472 | - |
| OPPOSITION | - THOMAS HAMACHER et al., "Efficacy and safety levels of preserved and preservative-free tafluprost are equivalents in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis", Acta Ophthalmol, (20080000), vol. 86, no. S242, pages 14 - 19, XP055974472 | - |
| OPPOSITION | - Touitou Elka, Barry Brian W, Boca Raton, London New, York, "Enhancement in Drug Delivery", Enhancement in Drug Delivery, CRC Press, (20070101), ISBN 978-0-429-12231-6, XP055976596 | - |
| OPPOSITION | - Touitou Elka, Brian W. Barry, "Ocular Penetration Enhancers", Enhancement in Drug Delivery, CRC Press, (20070101), pages 527 - 548, XP055976215 | - |
| OPPOSITION | - Uusitalo H., Et Al., "Pharmacokinetics, efficacy and safety profiles of preserved and preservative-free tafluprost in healthy volunteers", Acta Ophthalmol, (20080101), vol. 96, no. S242, pages 7 - 13, XP055974481 | - |
| OPPOSITION | - Y. KITAZAWA et al., "Travoprost 0.004%/timolol 0.5%-fixed combination with and without benzalkonium chloride: a prospective, randomized, doubled-masked comparison of safety and efficacy", Eye, (20110000), vol. 25, pages 1161 - 1169, XP055974488 | - |
| OPPOSITION | - Arthur Shedden; Ingrid A Adamsons; Albert J Getson; Jean K Laurence; Christopher R Lines; David J Hewitt; Tony W Ho, "Comparison of the efficacy and tolerability of preservative-free and preservative-containing formulations of the dorzolamide/timolol fixed combination (COSOPT™) in patients with elevated intraocular pressure in a randomized clinical trial", Graefes Arch Clin Exp Ophthalmol, (20100502), vol. 248, pages 1757 - 1764, XP019858805 | |
| OPPOSITION | - Manni, G. Centofanti, M. Oddone, F. Parravano, M. Bucci, M.G., "Interleukin-1@b tear concentration in glaucomatous and ocular hypertensive patients treated with preservative-free nonselective beta-blockers", American Journal of Ophthalmology, Elsevier, AMSTERDAM, NL, AMSTERDAM, NL , (20050101), vol. 139, no. 1, doi:10.1016/j.ajo.2004.08.028, ISSN 0002-9394, pages 72 - 77, XP004713606 | |
| OPPOSITION | - L. Jay Katz et al, "Twelve-Month, Randomized, Controlled Trial of Bimatoprost 0.01%, 0.0125%, and 0.03% in Patients with Glaucoma or Ocular Hypertension", American Journal of Ophthalmology, Elsevier, AMSTERDAM, NL, AMSTERDAM, NL , (20100401), vol. 149, no. 4, doi:10.1016/j.ajo.2009.12.003, ISSN 0002-9394, pages 661 - 671.e1, XP055580624 | |
| OPPOSITION | - A. G. P. KONSTAS, "Latanoprost 0.005% versus Bimatoprost 0.03% in primary open-angle glaucoma patients", American Academy of Ophthalmology, (20050000), vol. 112, doi:10.1016/j.ophtha.2004.08.022, pages 262 - 266, XP005825881 | |
| OPPOSITION | - Konstas A G P; Katsimbris J M; Lallos N; Boukaras G P; Jenkins J N; Stewart W C, "KONSTAS/au and 112-vol Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients", Opthalmology, (20050000), vol. 112, no. 2, pages 262 - 266, XP004730929 | |
| OPPOSITION | - Konstas, A.G.P. Katsimbris, J.M. Lallos, N. Boukaras, G.P. Jenkins, J.N. Stewart, W.C., "Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients", Ophthalmology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20050201), vol. 112, no. 2, doi:10.1016/j.ophtha.2004.08.022, ISSN 0161-6420, pages 262 - 266, XP004730929 | |
| OPPOSITION | - Baudouin Christophe, Labbé Antoine, Liang Hong, Pauly Aude, Brignole-Baudouin Françoise, "Preservatives in eyedrops: The good, the bad and the ugly", Prog. Retin. Eye Res., (20100000), vol. 29, no. 4, pages 312 - 334, XP055616054 | |
| OPPOSITION | - C. BAUDOUIN et al., "Preservatives in eyedrops - The good, the bad and the ugly", Progress in Retinal and Eye Research, (20100300), vol. 29, doi:10.1016/j.preteyeres.2010.03.001, pages 312 - 334, XP055616054 | |
| OPPOSITION | - Christophe Baudouin; Antoine Labbé; Hong Liang; Aude Pauly; Françoise Brignole-Baudouin, "Preservatives in eyedrops: The good, the bad and the ugly", Progress in Retinal and Eye Research, (20100300), vol. 29, pages 312 - 334, XP055616054 | |
| OPPOSITION | - CHRISTOPHE BAUDOUIN et al., "Preservatives in eyedrops - The good, the bad and the ugly", Progress in Retinal and Eye Research, (20100300), vol. 29, doi:10.1016/j.preteyeres.2010.03.001, pages 312 - 334, XP055616054 | |
| OPPOSITION | - Bean, G.W. ; Camras, C.B., "Commercially Available Prostaglandin Analogs for the Reduction of Intraocular Pressure: Similarities and Differences", SURVEY OF OPHTHALMOLOGY., SURVEY OF OPHTHALMOLOGY INC., XX, XX , (20081101), vol. 53, no. 6, doi:10.1016/j.survophthal.2008.08.012, ISSN 0039-6257, pages S69 - S84, XP025691108 | |
| OPPOSITION | - CHRIS DE JONG et al., "Topical timolol with and without benzalkonium chloride: epithelial permeability and autofluorescence of the cornea in glaucoma", Graefe's Arch. Clin. Exp. Ophthalmol., (19940000), vol. 232, doi:10.1089/jop.2010.0060, pages 221 - 224, XP055629307 | |
| OPPOSITION | - Chris De Jong; Thorsten Stolwijk; Esmeralda Kuppens; Rob De Keizer; Jaap Van Best, "Topical timolol with and without benzalkonium chloride: epithelial permeability and autofluorescence of the cornea in glaucoma", Graefe's Arch. Clin. Exp. Ophthalmol., (19940000), vol. 232, pages 221 - 224, XP055629307 | |
| OPPOSITION | - Chris De Jong, Thorsten Stolwijk, Esmeralda Kuppens, Rob De Keizer, Jaap Van Best, "Topical timolol with and without benzalkonium chloride: epithelial permeability and autofluorescence of the cornea in glaucoma", Graefe's Arch. Clin. Exp. Ophthalmol., (19940101), vol. 232, doi:10.1089/jop.2010.0060, pages 221 - 224, XP055629307 | |
| OPPOSITION | - DE JONG, C. et al., "Topical timolol with and without benzalkonium chloride: epithelial permeability and autofluorescence of the cornea in glaucoma", Graefe's Arch. Clin. Exp. Ophthalmol., (19940000), vol. 223, pages 221 - 224, XP055629307 | |
| OPPOSITION | - Giulia Renieri; Katrin Führer; Karl Scheithe; Katrin Lorenz; Norbert Pfeiffer; Hagen Thieme, "Efficacy and Tolerability of Preservative-Free Eye Drops Containing a Fixed Combination of Dorzolamide and Timolol in Glaucoma Patients", Journal of Ocular Pharmacology and Therapeutics, (20100000), vol. 26, no. 6, pages 597 - 603, XP055629222 | |
| OPPOSITION | - Giulia Renieri, Katrin Führer, Karl Scheithe, Katrin Lorenz, Norbert Pfeiffer, Hagen Thieme, "Efficacy and Tolerability of Preservative-Free Eye Drops Containing a Fixed Combination of Dorzolamide and Timolol in Glaucoma Patients", Journal of Ocular Pharmacology and Therapeutics, MARY ANN LIEBERT, INC., NEW YORK, NY., US, US , (20101201), vol. 26, no. 6, doi:10.1089/jop.2010.0060, ISSN 1080-7683, pages 597 - 603, XP055629222 | |
| OPPOSITION | - G. RENIERI et al., "Efficacy and Tolerability of Preservative-Free Eye Drops Containing a Fixed Combination of Dorzolamide and Timolol in Glaucoma Patients", J. of Ocular Pharm. And Therap., (20100000), vol. 26, no. 6, doi:10.1089/jop.2010.0060, XP055629222 | |
| OPPOSITION | - G. RENIERI et al., "Efficacy and tolerability of preservative-free eye drops", Journal of Ocular Pharmacology and Therapeutics, (20100000), vol. 26, no. 6, doi:10.1089/jop.2010.0060, pages 597 - 603, XP055629222 | |
| OPPOSITION | - Skov Anne Guldhammer, Rives Amalie Santaolalla, Freiberg Josefine, Virgili Gianni, Azuara‐blanco Augusto, Kolko Miriam, "Comparative efficacy and safety of preserved versus preservative‐free beta‐blockers in patients with glaucoma or ocular hypertension: a systematic review", Acta Ophthalmologica, (20210000), vol. 100, no. 3, pages 253 - 261, XP055974534 | |
| OPPOSITION | - CHRISTOPHE BAUDOUIN, "Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma", Acta Ophthalmologica, (20080000), vol. 86, doi:10.1111/j.1755-3768.2008.01250.x, pages 716 - 726, XP055603673 | |
| OPPOSITION | - Christophe Baudouin, "Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma", Acta Ophthalmologica: the ophthalmological journal of the Nordic countries, Wiley-Blackwell Munksgaard, Denmark, Denmark , (20081101), vol. 86, no. 7, doi:10.1111/j.1755-3768.2008.01250.x, ISSN 1755-375X, pages 716 - 726, XP055603673 | |
| OPPOSITION | - M Q Rahman, D Tejwani, J A Wilson, I Bucher And K Ramaesh, "Microbial contamination of preservative free eye drops in multiple application containers", Br. J. Ophthalmol., (20060101), vol. 90, doi:10.1136/bjo.2005.078386, pages 139 - 141, XP055629219 | |
| OPPOSITION | - P. J. PISELLA et al., "Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication", British Journal of Ophthalmology, (20020000), vol. 86, doi:10.1136/bjo.86.4.418, pages 418 - 423, XP055629318 | |
| OPPOSITION | - Day Douglas G, Walters Thomas R, Schwartz Gail F, Mundorf Thomas K, Liu Charlie, Schiffman Rhett M, Bejanian Marina, "Bimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trial", Br. J. Ophthalmol., (20130000), vol. 97, no. 8, pages 989 - 993, XP055974528 | |
| OPPOSITION | - Day Douglas G; Walters Thomas R; Schwartz Gail F; Mundorf Thomas K; Liu Charlie; Schiffman Rhett M; Bejanian Marina, "Bimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trial", Br. J. Ophthalmol., (20130000), vol. 97, pages 989 - 993, XP055974528 | |
| OPPOSITION | - GOLDBERG et al., "Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial", British Journal of Ophthalmology, (20140000), vol. 98, no. 7, pages 926 - 931, XP055603671 | |
| OPPOSITION | - Ivan Goldberg, Rafael Gil Pina, Aitor Lanzagorta-Aresti, Rhett M Schiffman, Charlie Liu, Marina Bejanian, "Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial", BRITISH JOURNAL OF OPHTHALMOLOGY, BMJ Publishing Group, GB, GB , (20140701), vol. 98, no. 7, doi:10.1136/bjophthalmol-2013-304064, ISSN 0007-1161, pages 926 - 931, XP055603671 | |
| OPPOSITION | - Ivan Goldberg, Rafael Gil Pina, Aitor Lanzagorta-Aresti, Rhett M Schiffman, Charlie Liu, Marina Bejanian, "Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial", BRITISH JOURNAL OF OPHTHALMOLOGY, GB , (20140701), vol. 98, no. 7, doi:10.1136/bjophthalmol-2013-304064, ISSN 0007-1161, pages 926 - 931, XP055603671 | |
| OPPOSITION | - Ivan Goldberg, Rafael Gil Pina, Aitor Lanzagorta-Aresti, Rhett M Schiffman, Charlie Liu, Marina Bejanian, "Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial", Br. J. Ophthalmol., (20140000), vol. 98, pages 926 - 931, XP055603671 | |
| OPPOSITION | - Hedengran Anne, Steensberg Alvilda T, Virgili Gianni, Azuara-Blanco Augusto, Kolko Miriam, "Efficacy and safety evaluation of benzalkonium chloride preserved eye-drops compared with alternatively preserved and preservative-free eye-drops in the treatment of glaucoma: a systematic review and meta-analysis", Br. J. Ophthalmol., (20200000), vol. 104, pages 1512 - 1518, XP055976477 | |
| OPPOSITION | - CHRISTOPHE BAUDOUIN et al., "In vitro studies of Antiglaucomatous Prostaglandin Analogues: Travoprost with and without Benzalkonium Chloride and Preserved Latanoprost", Invest. Ophthalmol. Vis. Sci., (20070000), vol. 48, doi:10.1167/IOVS.07-0266, pages 4123 - 4128, XP002607568 | |
| SEARCH | - Anonymous, "Package leaflet: Information for the userGANFORT 0.3 mg/ml + 5 mg/ml eye drops, solution, in single-dose containerBimatoprost/timolol", (2006), URL: https://www.medicines.org.uk/emc/files/pil.1239.pdf, XP002785284 [I] 3-6 * the whole document * [Y] 2,7-11 | - |
